Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies

Anna Lantz1,2 · Erik Skaaheim Haug3 · Wolfgang Picker4 · Alessio Crippa1 · Fredrik Jäderling2,5 · Ashkan Mortezavi1 · Tobias Nordström1,6

Received: 23 April 2020 / Accepted: 25 May 2020 / Published online: 29 May 2020 © The Author(s) 2020

Abstract

Purpose To describe the predictive value of information on previous benign biopsy for the outcome of MRI-targeted biopsies.

Methods An exploratory analysis was conducted using data from a prospective, multicenter, paired diagnostic study of 532 men undergoing diagnostics for prostate cancer during 2016–2017. All men underwent 1.5 T MRI; systematic prostate biopsies; and MRI-targeted biopsies to MRI lesions with Prostate Imaging Reporting and Data System version 2, PI-RADS ≥ 3. The main outcome was numbers of detected prostate cancer characterized by grade group (GG) where GG ≥ 2 defined clinically significant cancer (csPCa).

Results Men with previous biopsies had significantly more often negative MRI (26% vs. 17%, \( p < 0.05 \)) compared to men without previous biopsies. Men with previous biopsies showed higher rates of benign biopsies (41% vs. 26%, \( p < 0.05 \)) and lower rates of GG2 (17% vs. 30%, \( p < 0.05 \)) and GG ≥ 3 (5% vs. 10%, \( p < 0.05 \)) cancer. Biopsy-naïve men had higher proportions of highly suspicious MRI lesions (PIRADS 5; \( p < 0.05 \)) and a higher proportion of significant cancer in those lesions (\( p = 0.05 \)). In multivariate regression analysis, a previous benign prostate biopsy was associated with less than half the odds of csPCa (OR 0.38; 95% CI 0.20–0.71).

Conclusion In this large prospective multicenter trial, we showed that men with a previous prostate biopsy had higher proportions of MRIs without lesions and lower proportion of highly suspicious lesions than biopsy-naïve men. Further, biopsy-naïve men showed higher detection of clinically significant cancer when using MRI-targeted biopsies. Also, in the era of MRI-targeted biopsy strategies, biopsy history should be carefully considered in biopsy decisions.

Trial registration NCT02788825 (ClinicalTrials.gov). Date of registration June 2, 2016.

Keywords Prostate cancer · Prostate neoplasm · Prostate biopsy · Targeted biopsy · Magnetic resonance imaging · MRI

Introduction

Several studies have shown that MRI-targeted biopsy is superior to systematic transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer [1–3]. For example, the PRECISION trial reported that prostate biopsies targeted to MRI-visible lesions detected more clinically
significant cancer, less non-significant cancer and would safely spare some men with MRI not suggestive of prostate cancer from biopsy as compared with standard biopsies [1]. Recently, it was further demonstrated that a combined procedure combining targeted and systematic biopsies in men with visible MRI lesions enhances cancer detection and decreases risk of disease misclassification [4]. This supports the statement in EAU guidelines that this combined approach might be a suggested clinical standard [5].

Published studies however lack evidence whether this novel strategy for detection holds for both biopsy-naïve men and men with a previous prostate biopsy with a benign result. We recently published results from the paired design STHLM3MRI study where men without prior diagnosis of prostate cancer scheduled for prostate biopsy underwent both magnetic resonance imaging, systematic and two to three targeted fusion biopsies to any significant lesion defined as PIRADSv2 ≥ 3 at any of the three Scandinavian sites [6]. We found that a combination of a blood-based risk prediction tool and MRI-targeted biopsies can be used to inform biopsy decision making.

The aim of this analysis was to perform an exploratory analysis in the above cohort to evaluate how information on previous prostate biopsies affects MRI-targeted prostate biopsy outcomes to provide support for clinical decision making.

Methods

This study describes an exploratory analysis using data from the previously published STHLM3 MRI Phase 1 study [6].

Design

The STHLM3 MRI Phase study is a prospective, multicenter, paired diagnostic study registered as NCT02788825 (ClinicalTrials.gov). As previously described, men without prostate cancer, aged 45–75 years and referred for prostate biopsies or prebiopsy MRI, were recruited and underwent MRI and a combined prostate biopsy procedure. Any previous biopsy (yes/no) was reported by patients at study inclusion.

MRI procedure

MRI was performed using a standardized, short, detection protocol compliant with European Society of Radiology Guidelines PI-RADS v2, except that dynamic contrast enhancement was omitted to decrease protocol complexity and acquisition time. We used 1.5 T magnetic field strength scanner at all study sites, without an endorectal coil. The protocol included T1- and T2-weighted images; diffusion-weighted images; b-values of 100, 450, and 800 with a calculated apparent diffusion coefficient map (ADC); and a separately acquired b1500. The time of acquisition was 16 min for the MRI sequences per participant.

MRI scans were reported according to the modified Prostate Imaging Reporting and Data System version 2 (following the PI-RADS v2 guidelines, with the modification that a PI-RADS 3 lesion in the peripheral zone may not be upgraded to PI-RADS 4 based on dynamic contrast) with up to three lesions with PI-RADS grade ≥ 3 marked for targeted biopsies. Any of six highly experienced uroradiologists reviewed the MRI series.

Biopsy procedure

All participants underwent 10–12 systematic biopsies and patients with PI-RADS ≥ 3 underwent a combined biopsy procedure with two to three targeted biopsies to any marked lesion, performed by the same urologist. The systematic biopsies were sampled from the base, midpart and apex of the peripheral zone according to the Swedish National Guidelines for Prostate Cancer. The targeted biopsy procedure was performed before the systematic biopsies and by the same biopsying urologist. Targeted biopsies were undertaken using the Koelis system (Koelis Inc.), Artemis system (Eigen Inc.), or BioJet system (D&K Technologies GmbH). The systematic biopsies were performed without considering the location of the MRI lesions. The pathological specimen was locally reviewed by experienced uropathologists (SiV Tønsberg, Unilabs Stockholm, Oslo University Hospital). The biopsy cores were formalin fixed using separate containers and graded according to the International Society of Urological Pathology (ISUP) 2014 modification.

Statistical methods

A PI-RADS score of ≥ 3 defined significant MRI lesions. The highest recorded ISUP Grade Group (GG) from MRI-targeted and systematic biopsies in men with significant MRI lesions defined the primary outcome. Secondary outcome was the GG of MRI-targeted biopsies alone. Clinically significant cancer was defined as ISUP grade group ≥ 2 cancer. We report the biopsy outcomes stratified by PI-RADS score (≤ 2, 3, 4, 5). Proportions were compared using the McNemar test where p < 0.05 was considered statistically significant. We modelled the primary outcome in a univariate and a multivariate logistic regression including biopsy status (any previous prostate biopsy; yes/no), age (years), PSA (ng/ml), PSA density (ng/ml²), PI-RADS score and pathological finding on digital rectal examination (DRE; yes/no) as predictors. We evaluated the receiver operating characteristics of the fitted logistic models calculating the area under the curve (AUC), compared using the DeLong
method. All analyses were performed using Stata/MP 13.1 (Stata Corp., College Station, TX).

**Results**

Baseline characteristics are presented in Table 1. 27% \((n = 145)\) had a previous prostate biopsy with benign findings. In the overall cohort, the mean age was 58 years (SD 9) and median PSA density was 0.14 ng/ml\(^2\) [(IQR) 0.12], not statistically different between men with a previous biopsy and biopsy-naïve men. Men with a previous biopsy had significantly higher median PSA 8.0 vs. 6.0 ng/ml \((p < 0.001)\), more pathological findings on digital rectal examination (DRE) 36% vs. 10% \((p < 0.001)\), and less positive MRI findings (PI-RADS ≥ 3) 73% vs. 83% \((P 0.014)\) compared to biopsy-naïve men.

**Cancer detection**

There was a higher proportion of men with cancer findings among biopsy-naïve men than in men with a previous biopsy (57% vs. 33%, \(p < 0.05\)). Specifically, the proportion of men with clinically significant cancer was higher in biopsy-naïve men (33% vs. 22%; \(p < 0.05\); Table 2). Using systematic biopsies as end point, biopsy-naïve men showed a higher proportion GG1, GG2-3 and GG ≥4 findings, but lower proportion benign biopsy results. The median length of any cancer findings in systematic biopsies were longer in biopsy-naïve men than in previously biopsied men (10 mm vs. 5 mm; \(p < 0.05\)). The median length for any cancer finding on targeted biopsies was 15 mm (IQR 8–22) in biopsy-naïve men and 12 mm (IQR 4–22) in previously biopsied men (\(p = 0.2\)). Both when using systematic biopsies only and when omitting systematic biopsy results from the analysis, resembling the strategy of performing MRI-targeted biopsies only, we found a similar pattern (Table 2).

**MRI results**

19% \((n = 103)\) of men showed no significant lesion on MRI. This proportion was lower among biopsy-naïve men [17% \((n = 65)\)] than in men with a previous prostate biopsy, [26% \((n = 38)\)] \((p < 0.05)\); Table 3.

Further analyzing the cancer detection by MRI scorings, Table 3 shows that biopsy-naïve men more frequently showed highly suspicious lesions on MRI (PI-RADS 5; 23.5% vs. 15.2%, \(p < 0.05\)) and also showed higher detection of clinically significant cancer in those lesions than men with a previous biopsy (82.4% vs. 63.6%, \(p < 0.05\)). The negative predictive value of an MRI without significant lesions (PI-RADS ≤ 2) was 92.3 (95% CI 83.0–97.5) in biopsy-naïve men, 94.7% (95% CI 82.3–99.4) among men with a previous biopsy and 93.2% (95% CI 86.5–97.2) for the whole study population.

We then performed a multivariate regression model including biopsy status (yes/no) to assess any independent association of biopsy status with the risk of clinically significant cancer. Illustrated in Table 4, men with a previous biopsy show significantly lower odds of significant prostate cancer (OR 0.38; 95% CI 0.20–0.71) independent of the other clinical parameters. When using systematic biopsies, a previous biopsy was independently associated with a lower risk of significant cancer (OR 0.25; 95% CI 0.13–0.49). Comparing AUC values for discrimination of csPCa, previous biopsy status added value when only PSA was considered. However, this was not conveyed in an increasing AUC when adding biopsy status to a full clinical model using age, digital rectal examination, PSA and PSA density (Table 5). The ROC curves are displayed in Supplementary Fig. 1.

Finally, we assessed the added value of systematic biopsy in men with a significant lesion on MRI based on their biopsy status. Notably, omitting systematic biopsies in patients with a prior negative biopsy would have missed only two men (1.9%) with csPCa, but 18 (5.6%) in the biopsy-naïve cohort \((p = 0.07)\).

**Table 1** Participant characteristics

| Variable                  | All \((n = 532)\) | Biopsy naïve \((n = 387)\) | Previous benign biopsy \((n = 145)\) | \(p^*\) |
|---------------------------|-------------------|----------------------------|------------------------------------|--------|
| Age, year (mean, SD)      | 57.5 (9)          | 57.6 (9)                   | 57.4 (9)                           | 0.97   |
| PSA, ng/ml (median, IQR)  | 6.3 (4.4)         | 6.0 (4.2)                  | 8.0 (6.0)                          | <0.001 |
| PSA density, ng/ml\(^2\) (median, IQR) | 0.14 (0.12) | 0.13 (0.12) | 0.14 (0.11) | 0.10 |
| Digital rectal examination |                   |                            |                                    |        |
| Positive (%, \(n\))      | 28.8 (148)        | 9.9 (14)                   | 35.9 (134)                         | <0.001 |
| Negative (%, \(n\))      | 71.2 (366)        | 90.1 (127)                 | 64.1 (239)                         |        |
| MRI lesion (PI-RADS ≥ 3)  |                   |                            |                                    |        |
| Yes (%, \(n\))           | 80.6 (429)        | 83.2 (322)                 | 73.4 (107)                         | 0.014  |
| No (%, \(n\))            | 19.4 (103)        | 16.8 (65)                  | 26.2 (38)                          |        |

\*Comparing biopsy-naïve men and men with a previous benign biopsy

![Supplementary Fig. 1](https://example.com/supplementary-figure.png)
Discussion

In this exploratory analysis using data from a large prospective study of men undergoing MRI-targeted biopsies with or without the addition of systematic biopsies for prostate cancer detection, we demonstrate the added value of previous biopsy status for contemporary biopsy decisions. Our results show that men with a previous biopsy had significantly higher odds of MRI without significant lesions and lower odds of clinically significant prostate cancer, but no statistically significant difference in detection of non-significant prostate cancer. Correspondingly, biopsy-naive men show higher odds of highly suspicious MRI lesions and also a higher frequency of significant cancer in such lesions. Adjusting for other clinical factors, we show that the odds of finding significant cancer in a man is more than halved if he has undergone a previous prostate biopsy.

Our results show that a history of a previous negative biopsy is strongly associated with lower risk of finding significant prostate cancer. Furthermore, our results show that systematic biopsies miss 20% of csPCa and that the added value of systematic biopsies in men with a previous biopsy are limited when performing MRI-targeted biopsies.

Table 2 Prostate biopsy findings by PSA naivety for different diagnostic strategies

| Biopsy status                  | All (n = 532) | Biopsy naïve (n = 387) | Previous benign biopsy (n = 145) | p* |
|--------------------------------|---------------|------------------------|---------------------------------|----|
| Not performed, % (n)          | 19.4 (103)    | 16.8 (65)              | 26.2 (38)                       | 0.02|
| Benign, % (n)                 | 29.9 (159)    | 25.8 (100)             | 40.7 (59)                       | <0.01|
| Grade Group 1, % (n)          | 15.6 (83)     | 17.3 (67)              | 11.0 (16)                       | 0.07|
| Grade Group 2–3, % (n)        | 26.7 (142)    | 30.2 (117)             | 17.2 (25)                       | <0.01|
| Grade Group ≥ 4, % (n)        | 8.5 (45)      | 9.8 (38)               | 4.8 (7)                         | 0.07|

Using combined MRI-targeted biopsies without addition of systematic biopsies

| Biopsy status                  | Not performed | Benign, % (n) | Grade Group 1, % (n) | Grade Group 2–3, % (n) | Grade Group ≥ 4, % (n) |
|--------------------------------|---------------|---------------|----------------------|-----------------------|------------------------|
| Not performed                  | 19.9 (106)    | 34.2 (182)    | 14.3 (76)            | 24.3 (129)            | 7.3 (39)               |
| Benign, % (n)                  | 17.6 (68)     | 30.8 (119)    | 16.0 (62)            | 27.4 (106)            | 8.3 (32)               |
| Grade Group 1, % (n)           | 26.2 (38)     | 43.5 (63)     | 9.7 (14)             | 15.9 (23)             | 4.8 (7)                |
| Grade Group 2–3, % (n)         | 0.03          | 0.02          | 0.06                 | <0.01                 | 0.2                    |
| Grade Group ≥ 4, % (n)         | 0.03          | 0.02          | 0.06                 | <0.01                 | 0.2                    |

Using systematic biopsies

| Biopsy status                  | Benign, % (n) | Grade Group 1, % (n) | Grade Group 2–3, % (n) | Grade Group ≥ 4, % (n) |
|--------------------------------|---------------|----------------------|-----------------------|------------------------|
| Benign, % (n)                  | 50.6 (269)    | 19.0 (101)           | 24.1 (128)            | 6.4 (34)               |
| Grade Group 1, % (n)           | 42.1 (163)    | 21.2 (82)            | 28.2 (109)            | 8.5 (33)               |
| Grade Group 2–3, % (n)         | 73.1 (106)    | 13.1 (19)            | 13.1 (19)             | 0.7 (1)                |
| Grade Group ≥ 4, % (n)         | <0.01         | 0.03                 | <0.01                 | <0.01                  |

MRI-targeted biopsies were performed in men with significant MRI lesions defined as PI-RADS v2 ≥ 3. Results are displayed also when excluding results from systematic biopsies for men undergoing a targeted biopsy session.

*Comparing biopsy-naïve men and men with a previous benign biopsy

Table 3 MRI scorings and findings in corresponding target biopsy by biopsy naivety

| Biopsy naïve (n = 387) | Previous benign biopsy (n = 145) | p* | p* |
|------------------------|----------------------------------|----|----|
| Total                  | Total csPCa findings | nsPCa findings | Total csPCa findings | nsPCa findings | MRI | csPCa | nsPCa |
| PI-RADS score, % (n)   | % (n) | % (n) | % (n) | & (n) | % (n) | % (n) | % (n) | p | p | p |
| ≤ 2                    | 16.8 (65) | – | – | 26.1 (38) | – | – | <0.05 | – | – | – |
| 3                      | 36.2 (140) | 16.4 (23) | 20.7 (29) | 37.9 (55) | 12.7 (7) | 1.8 (1) | 0.7 | 0.5 | <0.05 |
| 4                      | 23.5 (91) | 44.0 (40) | 26.3 (24) | 20.7 (30) | 30.0 (9) | 30.0 (9) | 0.5 | 0.2 | 0.7 |
| 5                      | 23.5 (91) | 82.4 (75) | 9.9 (9) | 15.2 (22) | 63.6 (14) | 18.2 (4) | <0.05 | 0.05 | 0.3 |

Clinically significant prostate cancer (csPCa) was defined as ISUP grade group (GG) ≥ 2. Clinically non-significant cancer was defined as GG 1. Comparisons are described using p values from pairwise comparisons of proportions for MRI, csPCa and nsPCa findings between previously biopsied and biopsy-naive men
analysis of 5519 men from the placebo group in the Prostate Cancer Prevention Trial (PCPT), results showed that history of a previous negative biopsy was associated with a decreased risk of overall prostate cancer (OR 0.64; 95% CI 0.53–0.78) and high-risk prostate cancer (OR 0.70; 95% CI 0.49–0.99) [7]. Furthermore, results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown that a previous negative biopsy reduces the likelihood of a biopsy-detectable high-grade prostate cancer (OR 0.32; 95% CI 0.17–0.61) [8]. However, both these studies were performed before the introduction of MRI in prostate cancer diagnostics.

Multiple studies have shown that MRI-targeted biopsies more accurately detect clinically significant PC while also detecting less indolent PC, compared to systematic transrectal ultrasonography-guided biopsies in men at clinical risk for prostate cancer [1, 2]. MRI and targeted biopsies have been extensively analyzed in the literature in distinction to different scenarios, as addition to or replacement for systematic biopsies, in the setting of a previous negative biopsy, as initial biopsy or during active surveillance. Regarding previous biopsy status, some studies have shown that MRI-targeted biopsies improve the detection rate in men with a previous biopsy compared to systematic biopsies, however, not in biopsy-naïve men [9, 10]. Furthermore, existing randomized controlled trials, performed in biopsy-naïve men, have reported conflicting evidence in the detection rate of clinically significant prostate cancer evaluating MRI with MRI-targeted biopsies vs. systematic biopsies [1, 11–13]. Thus, EAU guidelines recommend the use of MRI and targeted biopsies, in the setting of persistent clinical suspicion of prostate cancer in men with a previous negative biopsy. If the MRI is negative and clinical suspicion of prostate cancer remains, guidelines suggest performing systematic biopsy based on shared decision making with the patient.

Is there any evidence to support whether men with normal MRI need systematic biopsies if they had a prior benign biopsy? In a prospective multicenter randomized trial, including 665 men with a prior negative systematic biopsy and a persistent suspicion of prostate cancer (by either suspicious DRE or PSA > 4.0 ng/ml), results show that only 1.3% of clinically significant prostate cancers would have been missed if systematic biopsies had been omitted [14]. The authors conclude that the value of repeat systematic biopsies is limited in this setting.

Our results show when comparing AUC values for discrimination of clinically significant prostate cancer.

### Table 4

|                      | Univariate analysis | Multivariate analysis |
|----------------------|--------------------|-----------------------|
|                      | OR  | 95% CI | OR  | 95% CI |
| Using MRI-targeted biopsies |     |        |     |        |
| Previous biopsy, years/n | 0.47 | 0.30–0.74 | 0.38 | 0.20–0.71 |
| Age, years            | 0.98 | 0.95–0.99 | 1.00 | 0.97–1.03 |
| PSA, total            | 1.08 | 1.05–1.12 | 1.01 | 0.94–1.09 |
| PSA density, ng/ml/cc (100) | 1.07 | 1.05–1.09 | 1.04 | 1.01–1.07 |
| PI-RADS score, ≤2–5   | 5.10 | 3.87–6.72 | 4.58 | 3.32–6.31 |
| Digital rectal examination, pathological, 1/0 | 4.20 | 2.83–6.23 | 1.48 | 0.85–2.57 |
| Using systematic biopsies |     |        |     |        |
| Previous biopsy, years/n | 0.28 | 0.17–0.46 | 0.25 | 0.13–0.49 |
| Age, years            | 1.00 | 0.98–1.02 | 1.00 | 0.98–1.03 |
| PSA, total            | 1.08 | 1.04–1.11 | 1.03 | 0.96–1.10 |
| PSA density, ng/ml/cc (100) | 1.06 | 1.04–1.08 | 1.06 | 1.03–1.09 |
| Digital rectal examination, pathological, 1/0 | 5.26 | 3.52–7.86 | 4.32 | 2.71–6.90 |

### Table 5

|                      | MRI-targeted biopsies with addition of systematic biopsies | MRI-targeted biopsies | Systematic biopsies |
|----------------------|----------------------------------------------------------|----------------------|---------------------|
|                      | AUC | | AUC | |
| Total PSA            | 0.60 | | 0.62 | 0.61 |
| Total PSA + Biopsy naivety | 0.66 | | 0.67 | 0.70 |
| Clinical model       | 0.79 | | 0.81 | 0.80 |
| Clinical model + Biopsy naivety | 0.79 | | 0.80 | 0.81 |

Clinical model includes age, digital rectal examination, PSA, PSA-density
previous biopsy status added value when only PSA was considered, however not when a clinical model including age PSA and PSA density was compared. Radtke et al. retrospectively analyzed 1015 men who underwent MRI prior to MRI/transrectal ultrasound fusion biopsy between 2012 and 2015. They added pre-biopsy MRI data to the ERSPC risk calculator to develop risk models for prediction of significant prostate cancer in biopsy-naive men \( (n = 660) \) and men after previous biopsy \( (n = 355) \). Their results also show that a previous negative biopsy was a significant predictor of clinically significant prostate cancer \( (p = 0.006) \). Furthermore, similar to our findings, their risk model, including MRI PI-RADS, PSA, age, prostate volume and DRE, reached a higher AUC at 0.83 for biopsy-naïve men, compared to an AUC of 0.81 in the same model for men with a previous biopsy [15]. Several studies have evaluated the combined systematic and targeted biopsies to assess the added value of each technique. These studies are merged in a recent Cochrane meta-analysis, including 43 studies, and results show that MRI and targeted biopsies are superior to systematic biopsies in making a correct diagnosis of clinically significant prostate cancer. In a stratified analysis based on previous biopsy status, using MRI-targeted biopsies, men with a previous negative biopsy were 44% more likely to make the correct diagnosis of clinically significant prostate, buts 5% in biopsy-naïve men, compared to systematic biopsies [3]. Thus, current evidence indicates that knowledge of previous biopsy history should be included in biopsy decisions and prediction models for clinically significant prostate cancer.

Our study has several strengths. First, this multi-center, prospective study using a paired design was specifically designed to study real-life performance of targeted biopsies. We use a structured and high-qualitative, short radiology protocol developed for early detection of prostate cancer and highly experienced uroradiologists to ensure high radiological quality. However, there are also obvious limitations. We present a pragmatic, exploratory analysis that was not pre-specified in the study protocol and conclusions are therefore primarily hypothesis generating. Second, we lack information on type and time span from the previous biopsy procedure which could impact the results. Third, the systematic biopsy was performed unblinded from the MRI results, possibly affecting the results of the systematic biopsies. Finally, although it has previously been shown that targeted biopsies decrease disease misclassification as compared with traditional biopsies [4], the true disease prevalence is unknown.

**Conclusion**

In this large prospective multicenter study, we showed that men with a previous prostate biopsy had higher proportions of MRIs without lesions and lower proportion of highly suspicious lesions than biopsy-naïve men. Further, biopsy-naïve men showed higher detection of clinically significant cancer when using MRI-targeted biopsies and the added value of systematic biopsies in these men was limited. Also, in the era of MRI-targeted biopsy strategies, biopsy history should be carefully considered in biopsy decisions.

**Acknowledgements** Open access funding provided by Karolinska Institute. We thank all study participants and the STHLM3 core management group for taking care of all contact with participants, organising the databases and performing analyses. Further, we thank participating radiology and urology departments for taking care of participants and performing MRIs and prostate biopsies. We are thoroughly grateful especially to radiologists, Wolfgang Picker and Beata Gajdzik (Aleris Cancer Centrum), Tom Werner Olsen (SiV Tonsberg), uroradiologists Sven Löffler, Adrian Halland, Dag Gullan (SiV Tonsberg); Espen Kvan, Leif Erik Grotmøn (Aleris Cancer Centrum); Stefan Knutsson, Magnus Annerstedt (Urologi STHLM); Olaf Janson, Xiaoli Fang, Magnus Törnblom (UroClinic), Dushanka Kristiansson (UroPraxis) and Rodolfo Sanchez Sala (Karolinska University Hospital).

**Author contributions** AL: data analysis, manuscript writing. ESH: project development, data collection, data analysis, manuscript editing. WP: project development, data collection, data analysis, manuscript editing. AC: data analysis, manuscript editing. FJ: project development, data collection, data analysis, manuscript editing. AM: data analysis, manuscript editing. TN: project development, data collection, data analysis, manuscript writing.

**Funding** This study was funded by the Swedish Cancer Society (Cancerfonden) (Grant No: JCIA 19-0089, PJ 19-0131), Stockholm County Council (Grant No: k0173-2016) and Åke Wiberg fund (Grant No: M19-0384).

**Data availability** This manuscript has associated data which will not be deposited.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** The regional ethics committees in Stockholm and Oslo approved the study (2016/392-31 and 2016/684).

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in
References

1. Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777. https://doi.org/10.1056/NEJMoa1801993

2. Rouvière O, Puech P, Renard-Penna R et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100–109. https://doi.org/10.1016/S1470-2045(18)30569-2

3. Drost F-JH, Osses DF, Nieboer D et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:CD012663. https://doi.org/10.1002/14651858.CD012663.pub2

4. Ahdoot M, Wilbur AR, Reese SE et al (2020) MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 382:917–928. https://doi.org/10.1056/NEJMoa1910038

5. Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003

6. Grönberg H, Eklund M, Picker W et al (2018) Prostate cancer diagnostics using a combination of the stockholm3 blood test and multiparametric magnetic resonance imaging. Eur Urol 74:722–728. https://doi.org/10.1016/j.eururo.2018.06.022

7. Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. JNCI J Natl Cancer Inst 98:529–534. https://doi.org/10.1093/jnci/dji131

8. Roobol MJ, van Vught HA, Loeb S et al (2012) Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 61:577–583. https://doi.org/10.1016/j.eururo.2011.11.012

9. Schoots IG, Roobol MJ, Nieboer D et al (2014) Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68:438–450. https://doi.org/10.1016/j.eururo.2014.11.037

10. Valerio M, Donalson I, Emberton M et al (2015) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 68:8–19. https://doi.org/10.1016/j.eururo.2014.10.026

11. Baco E, Rud E, Eri LM et al (2015) A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy. Eur Urol. https://doi.org/10.1016/j.eururo.2015.03.041

12. Porpiglia F, Manfredi M, Mele F et al (2017) Diagnostic pathway with multiparametric magnetic resonance imaging versus standard pathway: results from a randomized prospective study in biopsy-naïve patients with suspected prostate cancer. Eur Urol 72:282–288. https://doi.org/10.1016/j.eururo.2016.08.041

13. Tonttila PP, Lantto J, Pääkkö E et al (2015) Prebiopsy multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naïve men with suspected prostate cancer based on elevated prostate-specific antigen values: results from a randomized prospective blinded controlled trial. Eur Urol. https://doi.org/10.1016/j.eururo.2015.05.024

14. Exterkate L, Wegelin O, Barentsz JO et al (2019) Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate? Eur Urol Oncol. https://doi.org/10.1016/j.euo.2019.06.005

15. Radtke JP, Wiesenfarth M, Kesch C et al (2017) Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol 72:888–896. https://doi.org/10.1016/j.eururo.2017.03.039

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.